AcquisitionOther
Rallybio Corporation acquired Candid Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Rallybio Corporation -> Candid Therapeutics, Inc.
Combined company advances T-cell engager therapeutics for autoimmune diseases with concurrent $505 million financing.
Open source record (SEC) ↗